Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced on Oct. 18, 2021, the filing of two new Provisional Patent applications focused on cancer treatment, particularly colorectal cancer. This adds to the company's IP portfolio, which now consists of 8 patent families, including 5 granted patents and 19 pending applications. Executive Chairman Gabriel Yariv emphasized the importance of these patents for addressing unmet needs in colorectal cancer therapy. The company is known for developing cannabinoid-based medicines for cancer treatment.
- Filing of 2 new Provisional Patent applications enhances intellectual property.
- Total IP portfolio now includes 8 patent families with 5 granted patents and 19 pending applications.
- Focus on colorectal cancer therapy addresses significant unmet medical needs.
- None.
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
These patent applications are now part of the Company's growing IP portfolio comprising of 8 Patent Families with 5 Granted patents and 19 Pending applications. Claims in Company's IP Portfolio include Pharmaceutical Compositions, Systems and Methods.
Gabriel Yariv, Cannabics Pharmaceuticals Executive Chairman, said: "We are pleased to announce that we have filed for 2 new Provisional Patents. The new patents will run in conjunction with our existing IP, granting the company protection over our cancer treatment compositions and methods including early intervention therapy for colorectal cancer, which remains an important unmet need for colorectal cancer patients."
Read more:
Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.). Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.
Logo - https://mma.prnewswire.com/media/796838/Cannabics_Pharmaceuticals_Logo_v2.jpg
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
+1 (877) 424-2429
info@cannabics.com
Related Links
https://cannabics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-files-2-provisional-patents-on-compositions-and-methods-for-treating-cancer-301402227.html
SOURCE Cannabics Pharmaceuticals Inc.
FAQ
What are the new patents filed by Cannabics Pharmaceuticals related to?
How many patents does Cannabics Pharmaceuticals currently have?
When did Cannabics Pharmaceuticals file the new patent applications?
What is the stock symbol for Cannabics Pharmaceuticals?
What is the significance of the new patent filings for Cannabics Pharmaceuticals?
